未治療のEGFR遺伝子変異陽性進行非小細胞肺がんを対象にしたランダム化比較第III相試験(ARCHER 1050)で、dacomitinibがゲフィチニブとの比較でOS改善【JCO】

J Clin Oncol. 2018 Jun 4

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations

 

コメント

Leave a comment

Your email address will not be published.


*